TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39515856

Group type: EXPERIMENTAL
Intervention: Individual target transcranial magnetic stimulation (IT-TMS) combined with antidepressant medication
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 68
Study: 39515867

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 µg/kg/h after anaesthesia induction until dural closure, then 0.08 µg/kg/h for 48 hours postoperatively)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo (normal saline, equal amounts of sufentanil and antiemetics, no dexmedetomidine)
Number of subjects: 366
Study: 39515988

Group type: EXPERIMENTAL
Intervention: 40% dextrose gel
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 169
Study: 39516087

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 213

Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 213

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 213
Study: 39516302

Group type: EXPERIMENTAL
Intervention: Ring electrodes (2 mm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tip- and mini-electrodes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Distance up to 4 mm
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Unipolar electrograms with HF_rel above 10%
Number of subjects: 25
Study: 39516358

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (Q28) with vandetanib 300 mg od (f + v)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (f + p)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: High total RET expression
Number of subjects: 165
Study: 39516370

Group type: EXPERIMENTAL
Intervention: E7389-LF 2.1 mg/m plus nivolumab
Number of subjects: 35
Study: 39516454

Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg, subcutaneous)
Number of subjects: 244
Study: 39516456

Group type: EXPERIMENTAL
Intervention: Oxford Nanopore Technologies PromethION 2 solo system and Fabric GEM™ software
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clinically accredited short-read rapid genomic testing pipeline (Newborn Genomics Programme)
Number of subjects: 200
Study: 39516524

Group type: EXPERIMENTAL
Intervention: 12-week web-based foot-ankle exercise program (SOPeD software) plus usual care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 12-week web-based foot-ankle exercise program (SOPeD software)
Number of subjects: 62
Study: 39516558

Group type: EXPERIMENTAL
Intervention: IXA + BEV
Number of subjects: 76

Group type: COMPARATOR
Intervention: IXA
Number of subjects: 76
Study: 39516643

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined radiomics-clinical signature
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Higher radiomics score
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Radiomics score
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 89
Study: 39516710

Group type: EXPERIMENTAL
Intervention: fampridine (10 mg twice daily for 3.5 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 39516733

Group type: EXPERIMENTAL
Intervention: Menstrual cups (one reusable disc-shaped menstrual cup per participant)
Number of subjects: 402
Study: 39516806

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) intervention - watching ad-hoc videos showing Spanish regional landscapes and villages for approximately 4 minutes per day for three consecutive days.
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Multicomponent Physical Exercise (ME) intervention - aerobic and strength exercise for progressive training of the upper and lower limbs.
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: IVR + ME intervention - both cognitive and physical intervention.
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control Group (CG) - no specific intervention mentioned.
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 212
Study: 39516828

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (VLC)
Number of subjects: 184

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 184
Study: 39516844

Group type: EXPERIMENTAL
Intervention: Social network-based intervention
Number of subjects: 0
Study: 39516847

Group type: EXPERIMENTAL
Intervention: CHW-led home-based hypertension control program
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1068
Study: 39516883

Group type: EXPERIMENTAL
Intervention: Changes in central venous-to-arterial PCO
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: ΔP(v-a)CO
Number of subjects: 205
Study: 39517110

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV/r) administered twice daily (BD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin alone in pregnant women
Number of subjects: 0
Study: 39518090

Group type: EXPERIMENTAL
Intervention: Quality Indicators in the Treatment of NMIBC
Number of subjects: 0
Study: 39518689

Group type: EXPERIMENTAL
Intervention: Balloon-Expandable Covered Stenting
Number of subjects: 0
Study: 39519577

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39520048

Group type: EXPERIMENTAL
Intervention: Dostarlimab-gxly
Number of subjects: 868

Group type: COMPARATOR
Intervention: Dostarlimab-gxly with chemotherapy
Number of subjects: 868
Study: 39520262

Group type: EXPERIMENTAL
Intervention: Everyday Problems Test (EPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other IADL instruments
Number of subjects: 0
Study: 39520455

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39520501

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39520516

Group type: EXPERIMENTAL
Intervention: PSFA-01 (dual-targeting tracer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 39520605

Group type: EXPERIMENTAL
Intervention: BEACON Caresystem advice on tidal volume/inspiratory pressure, inspired oxygen, respiratory rate and PEEP
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (local clinical practice)
Number of subjects: 112
Study: 39520630

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 900

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 900
Study: 39520634

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed up to once daily for up to 52 weeks
Number of subjects: 1800
Study: 39520648

Group type: EXPERIMENTAL
Intervention: DB-macitentan patients (10 mg macitentan once-daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: DB-placebo patients
Number of subjects: 76
Study: 39520655

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/day
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383
Study: 39520738

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 6
Study: 39520893

Group type: EXPERIMENTAL
Intervention: MenABCWY
Number of subjects: 1379

Group type: COMPARATOR
Intervention: MenACWY-CRM (single dose)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: MenB-fHbp
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Booster dose
Number of subjects: 1379
Study: 39521008

Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis (1.0 mg/kg loading dose on day 1, followed by daily doses of 0.20 mg/kg, with options to adjust based on plasma concentration)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Concizumab prophylaxis
Number of subjects: 148

Group type: COMPARATOR
Intervention: No prophylaxis (on-demand clotting factor)
Number of subjects: 148
Study: 39521012

Group type: EXPERIMENTAL
Intervention: NmCV-5
Number of subjects: 1640

Group type: COMPARATOR
Intervention: MenACWY-D
Number of subjects: 1640
Study: 39521094

Group type: EXPERIMENTAL
Intervention: Endoscopic background mucosal resurfacing (EBMR) with radiofrequency ablation (RFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endoscopic surveillance alone (control group)
Number of subjects: 30
Study: 39521433

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every four weeks
Number of subjects: 669

Group type: COMPARATOR
Intervention: Chemotherapy every three weeks for four to six cycles
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 669

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 669
Study: 39521434

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Olaparib
Number of subjects: 672

Group type: COMPARATOR
Intervention: Pembrolizumab plus Pemetrexed
Number of subjects: 672
Study: 39521460

Group type: EXPERIMENTAL
Intervention: 24 mg buprenorphine maintenance daily dose
Number of subjects: 250

Group type: COMPARATOR
Intervention: 16 mg buprenorphine maintenance daily dose
Number of subjects: 250
Study: 39521467

Group type: EXPERIMENTAL
Intervention: High-flow only weaning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 20
Study: 39521475

Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (DTM SCS)
Number of subjects: 250
Study: 39521698

Group type: EXPERIMENTAL
Intervention: Coated miniscrews with chlorhexidine hexametaphosphate antimicrobial nanoparticles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated miniscrews
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coated miniscrews
Number of subjects: 40
Study: 39521884

Group type: EXPERIMENTAL
Intervention: Intravesical cretostimogene grenadenorepvec with systemic nivolumab
Number of subjects: 21
Study: 39521897

Group type: EXPERIMENTAL
Intervention: Video-based educational intervention about cooking-related pollutants and range hood replacement
Number of subjects: 14
Study: 39521970

Group type: EXPERIMENTAL
Intervention: A.S.K.-PrEP
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: A.S.K.-PrEP + Contingency Management (CM)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) alone
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 250
Study: 39522003

Group type: EXPERIMENTAL
Intervention: Co-Cr conventional casting bar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Co-Cr CAD/CAM milled bar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Co-Cr CAD/CAM 3D-printed bar
Number of subjects: 30
Study: 39522018

Group type: EXPERIMENTAL
Intervention: Behavioral Activation intervention (8 tele-therapy sessions over 10 weeks)
Number of subjects: 15
Study: 39522090

Group type: EXPERIMENTAL
Intervention: Alteplase (low- or high-dose) plus standard of care (SOC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 104
Study: 39522476

Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham therapeutic ultrasound
Number of subjects: 57
Study: 39522541

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab (240 mg intravenously) every 2 weeks for two cycles followed by concurrent cisplatin (100 mg/m2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo with concurrent cisplatin (100 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 39522584

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) for 28 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham intervention for 28 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 42
Study: 39522630

Group type: EXPERIMENTAL
Intervention: mLife+points
Number of subjects: 240

Group type: COMPARATOR
Intervention: mLife
Number of subjects: 240
Study: 39522641

Group type: EXPERIMENTAL
Intervention: sTIL levels in metastases
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sTIL levels in metastases from invasive lobular carcinoma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ER expression in metastases
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sTIL levels in lung and axillary lymph node metastases
Number of subjects: 20
Study: 39522654

Group type: EXPERIMENTAL
Intervention: Amlitelimab 250 mg every 4 weeks plus a 500-mg loading dose
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Amlitelimab 125 mg every 4 weeks
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Amlitelimab 62.5 mg every 4 weeks
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose) continued for 28 weeks after initial treatment
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose) stopped after initial treatment
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose)
Number of subjects: 390
Study: 39522714

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 103
Study: 39522752

Group type: EXPERIMENTAL
Intervention: Ophthalmologists
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Automated AI-based analysis
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham arm
Number of subjects: 134

Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 134
Study: 39522824

Group type: EXPERIMENTAL
Intervention: eRT (FDG-PET-guided dose painting and scheduled adaptive radiotherapy)
Number of subjects: 221
Study: 39522957

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg equivalent
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg equivalent
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Baricitinib 1-mg equivalent
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 39523312

Group type: EXPERIMENTAL
Intervention: NeoSealer Flo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MTA-Bioseal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: GuttaFlow bioseal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AH Plus epoxy resin-based sealer
Number of subjects: 120
Study: 39523352

Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study: 39523406

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention program, MyBFF@school Phase I (16 weeks) including physical activity, healthy eating promotion, and psychological empowerment.
Number of subjects: 102
Study: 39523423

Group type: EXPERIMENTAL
Intervention: Strength and power training (n=18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Strength training (n=19)
Number of subjects: 37
Study: 39523543

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (NMV/r) 300 mg/100 mg every 12 hours for 5 days
Number of subjects: 1966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1966
Study: 39523547

Group type: EXPERIMENTAL
Intervention: RSVpreF (120 µg)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study: 39523681

Group type: EXPERIMENTAL
Intervention: Disease Severity Index (DSI) calculated from clearances of labelled cholates after oral and intravenous administration
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Using DSI ≤ 18.3 as the sole determinant to defer EGD
Number of subjects: 306
Study: 39523874

Group type: EXPERIMENTAL
Intervention: Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% administered every 4 weeks (88.2%) or every 3 weeks (11.8%). Median 4-weekly IgG dose equivalent was 64.0 g (range 28.0-200.0 g).
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 85
Study: 39523878

Group type: EXPERIMENTAL
Intervention: Three standard doses of inactivated COVID-19 vaccines
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Two standard doses plus a double dose of inactivated COVID-19 vaccines
Number of subjects: 182

Group type: COMPARATOR
Intervention: Two doses of inactivated COVID-19 vaccines in healthy controls
Number of subjects: 182
Study: 39523954

Group type: EXPERIMENTAL
Intervention: Exercise intervention (30-50 min low-to-high intensity exercise 5 times/week for 8 weeks, starting one day after discharge)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 55
Study: 39524040

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 250

Group type: COMPARATOR
Intervention: Four-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 250
Study: 39524078

Group type: EXPERIMENTAL
Intervention: Viral load testing and suppression education
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adherence to ART
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Engagement with healthcare providers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experiences with viral load testing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Barriers to viral suppression
Number of subjects: 32
Study: 39524230

Group type: EXPERIMENTAL
Intervention: Acalabrutinib + Obinutuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acalabrutinib (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil + Obinutuzumab
Number of subjects: 0
Study: 39525336

Group type: EXPERIMENTAL
Intervention: Clinical decision support system
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1133
Study: 39525351

Group type: EXPERIMENTAL
Intervention: Microfracture (MFx)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Porcine-derived collagen-augmented chondrogenesis technique (C-ACT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: C-ACT
Number of subjects: 36
Study: 39525672

Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 vaccine booster dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated COVID-19 vaccine (Sinovac, China)
Number of subjects: 0
Study: 39525677

Group type: EXPERIMENTAL
Intervention: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (5 µg, 10 µg, and 20 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine
Number of subjects: 0
Study: 39525828

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing (LBBAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right Ventricular Septal Pacing (RVSP)
Number of subjects: 0
Study: 39525834

Group type: EXPERIMENTAL
Intervention: Telehealth support for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard physical education classes
Number of subjects: 34
Study: 39525874

Group type: EXPERIMENTAL
Intervention: Dance Group (DG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Martial Arts Group (MaG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study: 39525887

Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue of lipedema stages I, II, and III
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hypertrophied subcutaneous tissue
Number of subjects: 29
Study: 39525940

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) using the Sanvello smartphone application for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39526078

Group type: EXPERIMENTAL
Intervention: Etrasimod (2 mg or 1 mg, once daily)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study: 39526177

Group type: EXPERIMENTAL
Intervention: Early Palliative Care (EPC) plus standard oncological care (SOC)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Standard Oncological Care (SOC) alone
Number of subjects: 470
Study: 39526355

Group type: EXPERIMENTAL
Intervention: CDC infusion
Number of subjects: 93
Study: 39526563

Group type: EXPERIMENTAL
Intervention: Human milk intake (AHM)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Formula only (FO)
Number of subjects: 447
Study: 39526777

Group type: EXPERIMENTAL
Intervention: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up MRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electroencephalography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Abscess capsule FDG signal
Number of subjects: 40
Study: 39526779

Group type: EXPERIMENTAL
Intervention: High-dose 5-ALA (>40 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low/standard dose 5-ALA (<30 mg/kg)
Number of subjects: 31
Study: 39526836

Group type: EXPERIMENTAL
Intervention: Collaborative nursing care intervention
Number of subjects: 144
Study: 39526855

Group type: EXPERIMENTAL
Intervention: Low salt diet (1.5 g/day) for 3 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 194
Study: 39527055

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TMS-induced electric field strength
Number of subjects: 66
Study: 39527056

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg) in the first year
Number of subjects: 101

Group type: COMPARATOR
Intervention: Continuous denosumab treatment (60 mg twice yearly)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg) in the first year (ZOL subgroup with 3 or more years of denosumab treatment)
Number of subjects: 101
Study: 39527097

Group type: EXPERIMENTAL
Intervention: Nivolumab, trastuzumab, and anti-CTLA-4 ipilimumab (Ipi arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab, trastuzumab, and FOLFOX chemotherapy (FOLFOX arm)
Number of subjects: 0
Study: 39527163

Group type: EXPERIMENTAL
Intervention: OroSEP
Number of subjects: 341

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 341